Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic

[1]  C. Spencer,et al.  A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium , 2016, bioRxiv.

[2]  Hynek Pikhart,et al.  HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials , 2015, The Lancet.

[3]  A. Lipman.  Drug Repurposing and Repositioning: Workshop Summary , 2015 .

[4]  Li-Huei Tsai,et al.  Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons , 2014, Molecular Psychiatry.

[5]  N. Iwata,et al.  Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis , 2015, European Archives of Psychiatry and Clinical Neuroscience.

[6]  Y. Okada.  From the era of genome analysis to the era of genomic drug discovery: a pioneering example of rheumatoid arthritis , 2014, Clinical genetics.

[7]  Steve Olson,et al.  Drug Repurposing and Repositioning: Workshop Summary , 2014 .

[8]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[9]  J. Rawlins,et al.  What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit , 2014, Molecular Psychiatry.

[10]  Arthur Christopoulos,et al.  Muscarinic acetylcholine receptors: novel opportunities for drug development , 2014, Nature Reviews Drug Discovery.

[11]  M. Ostland,et al.  Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. , 2014, JAMA psychiatry.

[12]  Stephen T. C. Wong,et al.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. , 2014, Drug discovery today.

[13]  B. Kinon,et al.  Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison , 2014, Schizophrenia research and treatment.

[14]  M. Rask-Andersen,et al.  The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. , 2014, Annual review of pharmacology and toxicology.

[15]  Jun S. Liu,et al.  Genetics of rheumatoid arthritis contributes to biology and drug discovery , 2013 .

[16]  Peggy Hall,et al.  The NHGRI GWAS Catalog, a curated resource of SNP-trait associations , 2013, Nucleic Acids Res..

[17]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[18]  Chunyu Liu,et al.  A rare mutation of CACNA1C in a patient with Bipolar disorder, and decreased gene expression associated with a Bipolar-associated common SNP of CACNA1C in brain , 2013, Molecular Psychiatry.

[19]  J. Lindenmayer,et al.  Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo , 2013, Schizophrenia Research.

[20]  Joshua F. McMichael,et al.  DGIdb - Mining the druggable genome , 2013, Nature Methods.

[21]  D. Schoenfeld,et al.  Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia , 2013, Psychopharmacology.

[22]  F. Leweke,et al.  Repurposed drugs for the treatment of schizophrenia and bipolar disorders. , 2013, Current topics in medicinal chemistry.

[23]  Teri A. Manolio,et al.  Bringing genome-wide association findings into clinical use , 2013, Nature Reviews Genetics.

[24]  D. Altshuler,et al.  Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.

[25]  S. Akhondzadeh,et al.  Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study , 2013, Journal of clinical psychopharmacology.

[26]  C. Lines,et al.  Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophrenia , 2013, Human psychopharmacology.

[27]  T. Insel.  Next-Generation Treatments for Mental Disorders , 2012, Science Translational Medicine.

[28]  Bronwen L. Aken,et al.  GENCODE: The reference human genome annotation for The ENCODE Project , 2012, Genome research.

[29]  D. Javitt,et al.  A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. , 2012, The Journal of clinical psychiatry.

[30]  F. Iasevoli,et al.  Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. , 2012, European journal of pharmacology.

[31]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[32]  P. Keck,et al.  A Randomized, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain , 2012, Journal of clinical psychopharmacology.

[33]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[34]  Vidhi Singh,et al.  Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia , 2011, CNS drugs.

[35]  F. Collins.  Reengineering Translational Science: The Time Is Right , 2011, Science Translational Medicine.

[36]  B. Kinon,et al.  A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia , 2011, Journal of clinical psychopharmacology.

[37]  A. Arnsten.  Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia , 2011, International Journal of Developmental Neuroscience.

[38]  R. Perlis,et al.  L‐type calcium channels and psychiatric disorders: A brief review , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[39]  M. Berk,et al.  Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. , 2009, The Journal of clinical psychiatry.

[40]  J. Lieberman,et al.  A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia , 2009, Neuropsychopharmacology.

[41]  Craig Mallinckrodt,et al.  Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. , 2008, The American journal of psychiatry.

[42]  Yoshiaki Kawase,et al.  Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. , 2008, Journal of cardiac failure.

[43]  Michael F. Green,et al.  A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia , 2008, Neuropsychopharmacology.

[44]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[45]  S. Siegelbaum,et al.  HCN1 Channels Constrain Synaptically Evoked Ca2+ Spikes in Distal Dendrites of CA1 Pyramidal Neurons , 2007, Neuron.

[46]  D. Javitt,et al.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.

[47]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[48]  B. Wexler,et al.  Neuropsychological deficits in nonsmokers with schizophrenia: Effects of a nicotinic antagonist , 2006, Schizophrenia Research.

[49]  D. Alkon,et al.  Bryostatin-1: pharmacology and therapeutic potential as a CNS drug. , 2006, CNS drug reviews.

[50]  M. Gitlin.  Treatment-resistant bipolar disorder , 2006, Molecular Psychiatry.

[51]  D. Triggle.  L-type calcium channels. , 2006, Current pharmaceutical design.

[52]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[53]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[54]  S. Kapur,et al.  Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[55]  Christian C. Felder,et al.  Muscarinic mechanisms of antipsychotic atypicality , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[56]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[57]  G. Jayson,et al.  The clinical development of the bryostatins , 2002, Anti-cancer drugs.

[58]  K. Ellenbogen,et al.  Clinical and electrophysiologic effects of calcium channel blockers in patients receiving ibutilide. , 2002, American heart journal.

[59]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[60]  S. Akhondzadeh,et al.  Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia , 1999, Journal of clinical pharmacy and therapeutics.

[61]  L. Hollister,et al.  Calcium Channel Blockers in Psychiatric Disorders: A Review of the Literature , 1999, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[62]  K. S. Lee,et al.  Ionic mechanism of ibutilide in human atrium: evidence for a drug-induced Na+ current through a nifedipine inhibited inward channel. , 1998, The Journal of pharmacology and experimental therapeutics.

[63]  S. Deutsch,et al.  Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia. , 1997, Clinical neuropharmacology.

[64]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[65]  S. Kanba,et al.  Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. off. , 1996, Journal of clinical psychopharmacology.

[66]  A. Endo,et al.  The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.

[67]  R. Suddath,et al.  A clinical trial of nifedipine in schizophrenia and tardive dyskinesia , 1991, Pharmacology Biochemistry and Behavior.

[68]  W. Price.  Antipsychotic effects of verapamil in schizophrenia. , 1987, The Hillside journal of clinical psychiatry.

[69]  R. Shelton,et al.  A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia , 1986, Biological Psychiatry.